Prestige Consumer Healthcare (PBH) Return on Capital Employed (2011 - 2025)
Prestige Consumer Healthcare's (PBH) quarterly Return on Capital Employed came in at 9.68% in Q4 2025, down 58.0% year-on-year from 23.05% in Q4 2024, and down 3.63% quarter-over-quarter from 10.05% in Q3 2025.
Prestige Consumer Healthcare (PBH) Return on Capital Employed (2011 - 2025) Analysis & Trends
Prestige Consumer Healthcare's Return on Capital Employed history runs 15 years deep, the most recent figure standing at 9.68% for Q4 2025.
- On a quarterly basis, Return on Capital Employed fell 58.0% year-over-year to 9.68% in Q4 2025; TTM through Dec 2025 was 9.68%, a 58.0% decrease from a year earlier, with the FY2025 full-year figure at 10.35%, down 29.0% from the prior year.
- Return on Capital Employed fell to 9.68% in Q4 2025 per PBH's latest filing, from 10.05% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 10.66% in Q1 2024 and bottomed at 0.76% in Q2 2023.
- The 5-year median for Return on Capital Employed is 9.38% (2022), against an average of 7.63%.
- Across the five-year window, Return on Capital Employed tumbled 1010 bps in 2023 and soared 1132 bps in 2024, its largest moves.
- Year by year, Return on Capital Employed stood at 9.16% in 2021, then climbed by 3 bps to 9.45% in 2022, then tumbled by 107 bps to 0.65% in 2023, then soared by 1689 bps to 10.26% in 2024, then decreased by 6 bps to 9.68% in 2025.
- Per Business Quant, the three latest PBH Return on Capital Employed figures stand at 9.68% (Q4 2025), 10.05% (Q3 2025), and 10.17% (Q2 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 8.52% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 27.36% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -1.50% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 21.43% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 0.46% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 20.04% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 5.24% |
| 10 | Prestige Consumer Healthcare | 2.34 Bn | 2.28 Bn | 157.37 Mn | 9.68% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 9.68% |
| Sep 30, 2025 | 10.05% |
| Jun 30, 2025 | 10.17% |
| Mar 31, 2025 | 10.33% |
| Dec 31, 2024 | 10.26% |
| Sep 30, 2024 | 10.15% |
| Jun 30, 2024 | 10.29% |
| Mar 31, 2024 | 10.66% |
| Dec 31, 2023 | -0.65% |
| Sep 30, 2023 | -0.63% |
| Jun 30, 2023 | -0.76% |
| Mar 31, 2023 | -0.66% |
| Dec 31, 2022 | 9.45% |
| Sep 30, 2022 | 9.39% |
| Jun 30, 2022 | 9.25% |
| Mar 31, 2022 | 9.37% |
| Dec 31, 2021 | 9.16% |
| Sep 30, 2021 | 9.06% |
| Jun 30, 2021 | 9.16% |
| Mar 31, 2021 | 8.94% |